Olema Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences in February 2025.

The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 9:20 a.m. ET through a virtual presentation. Additionally, Olema will participate in Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025, at 10 a.m. ET in a virtual fireside chat format.

Live webcasts of both presentations will be accessible through the Events and Presentations section of Olema's investor relations website at ir.olema.com, with recordings available for at least 30 days after the events.

News Market Reaction

+3.52%

1 alert

+3.52% News Effect

On the day this news was published, OLMA gained 3.52%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that management will participate in the following investor conferences:

Oppenheimer 35^th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025 at 9:20 a.m. ET
Format: Virtual Presentation

Citi’s 2025 Virtual Oncology Leadership Summit
Date: Thursday, February 20, 2025 at 10 a.m. ET
Format: Virtual Fireside Chat

Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

What investor conferences will Olema Pharmaceuticals (OLMA) attend in February 2025?

Olema will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 and Citi's 2025 Virtual Oncology Leadership Summit on February 20.

When is Olema's (OLMA) presentation at the Oppenheimer Healthcare Conference 2025?

Olema will present at the Oppenheimer Healthcare Conference on Wednesday, February 12, 2025, at 9:20 a.m. ET.

How can investors access Olema's (OLMA) February 2025 conference presentations?

Investors can access live webcasts of the presentations through Olema's investor relations website at ir.olema.com in the Events and Presentations section.

How long will Olema's (OLMA) February 2025 conference webcasts be available?

The webcasts will be archived and available for at least 30 days after the events on Olema's investor relations website.

What is the format of Olema's (OLMA) presentation at Citi's 2025 Virtual Oncology Summit?

Olema will participate in a virtual fireside chat format at Citi's Virtual Oncology Leadership Summit on February 20, 2025, at 10 a.m. ET.